https://www.pharmaradar360.com/article/db6fc07b7811fc64PharmaRadar360en2026-05-02T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/6082553a36cd86f0PharmaRadar360en2026-05-02T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/50038331dc1d1f59PharmaRadar360en2026-05-02T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/d9f7d91c2db3cf84PharmaRadar360en2026-05-02T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/e573ceb2ad86009fPharmaRadar360en2026-05-02T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/8fdb736d07a24ae2PharmaRadar360en2026-05-02T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/7cbd0a51761e8484PharmaRadar360en2026-05-02T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/a83d0a12549245eaPharmaRadar360en2026-05-02T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/14804ccc92a29604PharmaRadar360en2026-05-02T00:00:00.000Zlegal update regarding risdiplamhttps://www.pharmaradar360.com/article/fed5d0d6b75300f3PharmaRadar360en2026-05-02T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/92b4e1ac7546a595PharmaRadar360en2026-05-02T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/128339e8d4edc66fPharmaRadar360en2026-05-02T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/24aa7d6a84ba43b0PharmaRadar360en2026-05-02T00:00:00.000Z6203https://www.pharmaradar360.com/article/bd1e13659d517ee6PharmaRadar360en2026-05-02T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/18e5611abad68c7ePharmaRadar360en2026-05-01T15:38:40.000ZField Safety Notices: 1 May 2026https://www.pharmaradar360.com/article/c2a055021b2d5966PharmaRadar360en2026-05-01T15:05:36.000ZDecision: Medical devices given exceptional use authorisations